Changing paradigm to target microglia in neurodegenerative diseases: From anti-inflammatory strategy to active immunomodulation

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 5, 2016, Pages 627-640

  Peña Altamira, Emiliano ^a   Prati, Federica ^a   Massenzio, Francesca ^a   Virgili, Marco ^a   Contestabile, Antonio ^a   Bolognesi, Maria Laura ^a   Monti, Barbara ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Drug targets; Immunomodulation; M2 and M1 phenotypes; Microglia; Neurodegenerative diseases

Indexed keywords

ANTIINFLAMMATORY AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOMODULATING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DOWN SYNDROME; DRUG TARGETING; GLIA CELL; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOMODULATION; MICROGLIA; NEURODEGENERATIVE DISEASES;

EID: 84949807682     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1121237     Document Type: Review

References (130)

1. Heneka MT, Carson MJ, El Khoury J., et al. Neuroinflammation in Alzheimer disease. Lancet Neurol. 2015; 14: 388-405.
2. Lawson LJ, Perry V, Dri PH., et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990; 39: 151-170.
3. Biber K, Owens T, Boddeke E. What is microglia neurotoxicity (not)? Glia. 2014; 62: 841-854.
4. Block ML, Zecca L, Hong J. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007; 8: 57-69.
5. Polazzi E, Monti B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol. 2010; 92: 293-215.
6. Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014; 158: 15-24.
7. Streit WJ, Xue QS. Life and death of microglia. J Neuroimmune Pharmacol. 2009; 4: 371-379.
8. Ginhoux F, Greter M, Leboeuf M., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010; 330: 841-845.
9. Elmore MR, Najafi AR, Koike MA., et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014; 82 (2): 380-397.
10. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014; 6 (6).
11. Mizuno T, Doi Y, Mizoguchi H., et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol. 2011; 179 (4): 2016-2027.
12. Walton NM, Sutter BM, Laywell ED., et al. Microglia instruct subventricular zone neurogenesis. Glia. 2006; 54: 815-825.
13. Ziv Y, Ron N, Butovsky O., et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nature Neurosci. 2006; 9: 268-275.
14. Xie Z, Smith CJ, Van Eldik LJ. Activated microglia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia. 2004; 45: 170-179.
15. Walker DG, Lue LE. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimers disease and other neurodegenerative diseases. J Neurosci. 2005; 81: 412-425.
16. Stence N1, Waite M, Dailey ME. Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia. 2001; 33 (3): 256-266.
17. Kozlowski C, Weimer RM. An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PLoS One. 2012; 7 (2): e31814.
18. Vinet J, Weering HR, Heinrich A., et al. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. J Neuroinflammation. 2012; 9: 27.
19. Ajami B, Bennet JL, Krieger C., et al. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007; 10: 1538-1543.
20. Hickey WE. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1991; 1: 97-105.
21. Biswas SK, Mantovani A. Macrophage elasticity and interactions with lymphocyte subsets: cancer as a paradigm. Nat Immun. 2010; 11: 889-896.
22. Gordon S, Martinez FO. Alternative activation of macrophages: mechanisms and functions. Immunity. 2010; 32: 593-604.
23. Clemente D, Ortega MC, Melero-Jerez C., et al. The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. Front Cell Neurosci. 2013; 7: 268.
24. Kigerl KA, Gensel JC, Ankeny DP., et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009; 29 (43): 13435-13444.
25. Schechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer "if" but "how". J Pathol. 2013; 229: 332-346.
26. Browne TC, McQuillan K, McManus RM., et al. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimers disease. J Immunol. 2013; 190 (5): 2241-2251.
27. Fletcher JM, Lalor SJ, Sweeney CM., et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010; 162: 1-11.
28. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol. 2101; 6: 405-410.
29. Horsch EC, Hunot S. Neuroinflammation in Parkinsons disease: a target for neuroprotection? Lancet Neurol. 2009; 8: 382-397.
30. Teismann P, Ferger B. Inhibition of the cycloxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinsons disease. Synapse. 2001; 39: 167-174.
31. Chen H, Zhang SM, Hernan MA., et al. Nonsteroidal antiinflammatory drugs and the risk of Parkinsons disease. Arch Neurol. 2003; 60: 1059-1064.
32. Gao X, Chen H, Schwarzschild MA., et al. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011; 76: 863-869.
33. Rees K, Stowe R, Patel S., et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinsons disease: evidence from observational studies. Cochrane Database Syst Rev. 2011; 11: CD008454. DOI: 10.1002/14651858.CD008454.pub2.
34. Henkel JS, Beers DR, Zhao W., et al. Microglia in ALS: the good, the bad and the resting. Neuroimmune Pharmacol. 2009; 4: 389-398.
35. Drachman DB, Frank K, Dykes-Hober M., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002; 52: 771-778.
36. Zhu S, Stavrovskaya IG, Drozda M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002; 417: 74-78.
37. Gordon PH, Moore DH, Miller RG., Et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007; 6: 1045-1053.
38. Swash M. Learning from failed trials in ALS. Lancet Neurol. 2007; 6: 1034-1035.
39. Contestabile A. Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr Med Chem. 2011; 18: 5655-5665.
40. Peviani M, Caron I, Pizzasegola C., et al. Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. CNS Neurol Disord Drug Targets. 2010; 9 (4): 491-503.
41. Shoemaker JL, Seely KA, Reed RL., et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007; 101: 87-98.
42. Yiangou Y, Facer P, Durrenberger P., et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006; 6: 12.
43. De Lago E, Fernández-Ruiz J. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol Disord Drug Targets. 2007; 6 (6): 377-387.
44. Thériault P, ElAli A, Rivest S. The dynamics of monocytes and microglia in Alzheimers disease. Alzh Res Ther. 2015; 7. doi: 10.1186/s13195-015-0125-2.
45. Lim GP, Yang F, Chu T., et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001; 22: 983-991.
46. Biscaro B, Lindvall O, Tesco G., et al. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimers disease. Neurodegener Dis. 2012; 91: 87-98.
47. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimers disease: a review of 17 epidemiological studies. Neurology. 1996; 47: 425-432.
48. The Alzheimers Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimers disease anti-inflammatory prevention trial (ADAPT). Alz Demen. 2013; 9: 714-723.
49. Jaturapatporn D, Isaac M, McCleery J., et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimers disease (Review). Cochrane Database Syst Rev. 2012; Art. No.: CD006378. DOI: 10.1002/14651858.CD006378.pub2.
50. Solas M, Francis PT, Franco R., et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimers disease patients. Neurobiol Aging. 2013; 34 (3): 805-808.
51. Aso E, Juvés S, Maldonado R., et al. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alzheimers Dis. 2013; 35 (4): 847-858.
52. Pascual AC, Martín-Moreno AM, Giusto NM., et al. Normal aging in rats and pathological aging in human Alzheimers disease decrease FAAH activity: modulation by cannabinoid agonists. Exp Gerontol. 2014; 60: 92-99.
53. Lott IT, Head E. Down syndrome and Alzheimers disease: a link between development and aging. Ment Retard Dev Disabil Rev. 2001; 7: 172-178.
54. Xue QS, Streit WJ. Microglial pathology in Down syndrome. Acta Neuropathol. 2011; 122: 455-466.
55. Hunter CL, Bachman D, Granholm A-C. Minocycline prevents cholinergic loss in a mouse model of Downs syndrome. Ann Neurol. 2004; 56: 675-688.
56. Crotti A, Glass CK. The choreography of neuroinflammation in Huntingtons disease. Trends Immunol. 2015; 36: 364-373.
57. Norflus F, Nanje A, Gutekunst C-A., et al. Anti-inflammatory treatment with acetylsalicylate or refecoxib is not neuroprotective in Huntingtons disease transgenic mice. Neurobiol Dis. 2004; 17: 319-325.
58. Kumar A, Singh SK, Kumar V., et al. Huntingtons disease: an update of therapeutic strategies. Gene. 2015; 556: 91-97.
59. Hersch S, Fink K, Vonsattel JP., et al. Minocycline is protective in a mouse model of Huntingtons disease. Ann Neurol. 2003; 54 (6): 841.
60. Menalled LB, Patry M, Ragland N., et al. Comprehensive behavioral testing in the R6/2 mouse model of Huntingtons disease shows no benefit from CoQ10 or minocycline. PLoS One. 2010; 5 (3): e9793.
61. Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntingtons disease. Mov Disord. 2010; 25 (13): 2219-2224.
62. Popovic N, Schubart A, Goetz BD., et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol. 2002; 51: 215-223.
63. Nikodemova M, Watters JJ, Jackson SJ., et al. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)/betaII. J Biol Chem. 2007; 282: 15208-15216.
64. Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2015. [Epub ahead of print].
65. Pepe G, Calderazzi G, De Maglie M., et al. Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4. J Neuroinflammation. 2014; 11: 211.
66. Kipnis J, Yoles E, Porat Z., et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A. 2000; 97 (13): 7446-7451.
67. Benner EJ, Mosley RL, Destache CJ., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinsons disease. Proc Natl Acad Sci U S A. 2004; 101 (25): 9435-9440.
68. Reynolds AD, Stone DK, Hutter JA., et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinsons disease. J Immunol. 2010; 184 (5): 2261-2271.
69. Butovsky O, Koronyo-Hamaoui M, Kunis G., et al. Glatiramer acetate fights against Alzheimers disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A. 2006; 103 (31): 11784.
70. Haenggeli C, Julien JP, Mosley RL., et al. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis. 2007; 26 (1): 146-152.
71. Meininger V, Drory VE, Leigh PN., et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009; 10 (5-6): 378-383.
72. English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015; 37 (4): 691-715.
73. Giunti D, Parodi B, Cordano C., et al. Can we switch microglias phenotype to foster neuroprotection? Focus Multiple Sclerosis Immunol. 2014; 141 (3): 328-339.
74. Chabot S, Yong FP, Le DM., et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler. 2002; 8 (4): 299-306.
75. Pul R, Moharregh-Khiabani D, Škuljec J., et al. Glatiramer acetate modulates TNF-α; and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmune Pharmacol. 2011; 6 (3): 381-388.
76. Burness CB1, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014; 28 (4): 373-387.
77. Wilms H, Sievers J, Rickert U., et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL- 1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010; 7: 30.
78. Foresti R, Bains SK, Pitchumony TS., et al. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res. 2013; 76: 132-148.
79. Wei Y, Yemisci M, Kim HH., et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011; 69 (1): 119-129.
80. Noda H, Takeuchi H, Mizuno T., et al. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013; 256 (1-2): 13-18.
81. Pawate S, Bagnato F. Newer agents in the treatment of multiple sclerosis. Neurologist. 2015; 19 (4): 104-117.
82. Novartis [Internet]. Basel [CH]: novartis AG; c2015. Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS); [. cited 2014 Dec 1]; [. about 8 screens]. Available from: https://www.novartis.com/news/media-releases/novartis-provides-update-fingolimod-phase-iii-trial-primary-progressive-ms-ppms
83. Kolb-Sobieraj C, Gupta S, Weinstock-Guttman B. Laquinimod therapy in multiple sclerosis: a comprehensive review. Neurol Ther. 2014; 3 (1): 29-39.
84. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntingtons disease: whats in the pipeline? Mov Disord. 2014; 29 (11): 1434-1445.
85. Huh SH, Chung YC, Piao Y., et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinsons disease. J Immunol. 2011; 187 (2): 960-969.
86. Shin JH, Kim ID, Kim SW., et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium. Mol Med. 2015; 20: 649-657.
87. Takata K, Kitamura Y, Tsuchiya D., et al. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res. 2004; 78 (6): 880-891.
88. Gao HM, Zhou H, Zhang F., et al. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 2011; 31 (3): 1081-1092.
89. Mollica L, Marchis FD, Spitaleri A., et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007; 14: 431-441.
90. Lee S, Nam Y, Koo JY., et al. A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. Nat Chem Biol. 2014; 10 (12): 1055-1060.
91. Giri S, Nath N, Smith B., et al. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004; 24 (2): 479-487.
92. Lu DY, Tang CH, Chen YH., et al. Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem. 2010; 110 (3): 697-705.
93. Zhang X, Zhang X, Wang C., et al. Neuroprotection of early and short-time applying berberine in the acute phase of cerebral ischemia: up-regulated pAkt, pGSK and pCREB, down-regulated NF-B expression, ameliorated BBB permeability. Brain Res. 2012; 1459: 61-70.
94. Haghani M, Shabani M, Tondar M. The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity. Eur J Pharmacol. 2015; 758: 82-88.
95. Chen CC, Hung TH, Lee CY., et al. Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury. PLoS One. 2014; 9 (12): e115694.
96. Jin Q, Cheng J, Liu Y., et al. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun. 2014; 40: 131-142.
97. Zhu XC, Jiang T, Zhang QQ., et al. Chronic metformin preconditioning provides neuroprotection via suppression of NF-B-mediated inflammatory pathway in rats with permanent cerebral ischemia. Mol Neurobiol. 2015; 52 (1): 375-385.
98. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol. 2010; 636 (1-3): 1-7.
99. Wang F, Cui N, Yang L., et al. Resveratrol rescues the impairments of hippocampal neurons stimulated by microglial over-activation In vitro. Cell Mol Neurobiol. 2015;35(7):1003-1015.
100. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009; 21 (2): 264-273.
101. Kondratiuk I, Devijver H, Lechat B., et al. Glycogen synthase kinase-3beta affects size of dentate gyrus and species-typical behavioral tasks in transgenic and knockout mice. Behav Brain Res. 2013; 248: 46-50.
102. Kimura T, Yamashita S, Nakao S., et al. GSK-3beta is required for memory reconsolidation in adult brain. PLoS One. 2008; 3 (10): e3540.
103. Palomo V, Perez DI, Perez C., et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem. 2012; 55 (4): 1645-1661.
104. Morales-García JA, Susín C, Alonso-Gil S., et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci. 2013; 4 (2): 350-360.
105. Prati F, De Simone A, Bisignano P., et al. Multitarget drug discovery for Alzheimers disease: triazinones as BACE-1 and GSK-3β inhibitors. Angew Chem Int Ed Engl. 2015; 54 (5): 1578-1582.
106. Prati F, De Simone A, Armirotti A., et al. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimers disease. ACS Chem Neurosci. 2015;6(10):1665-1682.
107. Serenó L, Coma M, Rodríguez M., et al. A novel GSK-3beta inhibitor reduces Alzheimers pathology and rescues neuronal loss in vivo. Neurobiol Dis. 2009; 35 (3): 359-367.
108. Onishi T, Iwashita H, Uno Y., et al. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimers disease. J Neurochem. 2011; 119 (6): 1330-1340.
109. Lovestone S, Boada M, Dubois B., et al. ARGO investigators. A phase II trial of tideglusib in Alzheimers disease. J Alzheimers Dis. 2015; 45 (1): 75-88.
110. Koh SH, Kim Y, Kim HY., et al. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol. 2007; 205 (2): 336-346.
111. Ahn SW, Jeon GS, Kim MJ., et al. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. J Neurol Sci. 2014; 340 (1-2): 112-116.
112. Suuronen T, Huuskonen J, Pihlaja R., et al. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem. 2003; 87 (2): 407-416.
113. Suuronen T, Huuskonen J, Nuutinen T., et al. Characterization of the pro-inflammatory signaling induced by protein acetylation in microglia. Neurochem Int. 2006; 49 (6): 610-618.
114. Chen PS, Wang CC, Bortner CD., et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 2007; 149 (1): 203-212.
115. Kim HJ, Rowe M, Ren M., et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007; 321 (3): 892-901.
116. Faraco G, Pittelli M, Cavone L., et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis. 2009; 36 (2): 269-279.
117. Chen SH, Wu HM, Ossola B., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br J Pharmacol. 2012; 165 (2): 494-505.
118. Wang G, Shi Y, Jiang X., et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis. Proc Natl Acad Sci U S A. 2015; 112 (9): 2853-2858.
119. Chen YC, Wu JS, Tsai HD., et al. Peroxisome proliferator- activated receptor gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol. 2012; 46 (1): 114-124.
120. Masciopinto F, Di Pietro N, Corona C., et al. Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis. 2012; 3: e448.
121. Savage JC, Jay T, Goduni E., et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimers disease. J Neurosci. 2015; 35 (16): 6532-6543.
122. Barbiero JK, Santiago RM, Persike DS., et al. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav Brain Res. 2014; 274: 390-399.
123. Pisanu A, Lecca D, Mulas G., et al. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinsons disease. Neurobiol Dis. 2014; 71: 280-291.
124. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinsons disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015; 14 (8): 795-803.
125. Schütz B, Reimann J, Dumitrescu-Ozimek L., et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005; 25 (34): 7805-7812.
126. Dupuis L, Dengler R, Heneka MT, et al.; GERP ALS Study Group. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012; 7 (6): e37885.
127. Feinstein DL, Galea E, Gavrilyuk V., et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol. 2002; 51 (6): 694-702.
128. Chen SH, Oyarzabal EA, Hong JS. Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration. Curr Opin Pharmacol. 2015; 26: 54-60.
129. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinsons disease and its potential as therapeutic target. Transl Neurodegener. 2015; 4: 19.
130. Von Bernhardi R, Eugenín-von Bernhardi L, Eugenín J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 2015; 7: 124.